Taylor, David, 1963-
Taylor, David M., 1963-....
David Taylor British pharmaceutical scientist
Taylor, David M., 19..-...., pharmacien
Taylor, David
Taylor, David, richtlijnen farmacie
Taylor, David M.
VIAF ID: 6236159477716927990001 (Personal)
Permalink: http://viaf.org/viaf/6236159477716927990001
Preferred Forms
- 100 0 _ ‡a David Taylor ‡c British pharmaceutical scientist
- 200 _ | ‡a Taylor ‡b David M.
-
- 100 1 _ ‡a Taylor, David M. ‡d 1963-
- 100 1 _ ‡a Taylor, David M. ‡d 1963-
- 100 1 _ ‡a Taylor, David M., ‡d 19..-...., ‡c pharmacien
- 100 1 _ ‡a Taylor, David M., ‡d 1963-....
-
-
-
- 100 1 _ ‡a Taylor, David, ‡d 1963-
- 100 1 _ ‡a Taylor, David, ‡d 1963-
-
4xx's: Alternate Name Forms (12)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
The Maudsley prescribing guidelines in psychiatry | |
Mozurei seishinka ni okeru shintai shikkan no shinryo gaidorain. | |
n 2017185137 | |
Naturalistic outcomes of community treatment orders: antipsychotic long-acting injections versus oral medication. | |
Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. | |
On spinning plates | |
Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis | |
Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota | |
Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials | |
Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy | |
The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks | |
Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors | |
Plasma levels of tricyclics and related antidepressants: are they necessary or useful? | |
Plasma Olanzapine Concentrations In Clinical Practice: UK Experience | |
Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. | |
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease | |
The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach. | |
Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. | |
Practitioner attitudes to clozapine initiation | |
Pramipexole in unipolar and bipolar depression | |
Predictors of long-term (≥6months) antipsychotic polypharmacy prescribing in secondary mental healthcare | |
Predictors of rehospitalization in a naturalistic cohort of patients with bipolar affective disorder. | |
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study | |
Prescription errors in psychiatry - a multi-centre study. | |
Prolongation of QTc interval and antipsychotics | |
Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome | |
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. | |
Psychiatric side effects of non-psychiatric drugs | |
Psychiatrists' attitude towards and knowledge of clozapine treatment | |
Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review | |
Psychotropic drugs, torsade de pointes and sudden death. | |
Psychotropic interactions with warfarin | |
Psychotropics and hyponatraemia | |
Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection | |
Resolution without discontinuation: heart failure during clozapine treatment | |
Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. | |
A review of the adverse effects and safety of noradrenergic antidepressants | |
Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine | |
Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. | |
Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up | |
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. | |
Schizophrenia in focus, c2006: | |
Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme | |
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? | |
Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients | |
Stahl’s illustrated. Antipsychotichs, treating psychosis, mania and depression | |
Tardive dyskinesia – how is it prevented and treated? | |
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). | |
A therapeutic interaction between cimetidine and clozapine: case study and review of the literature | |
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. | |
Tolerability of atypical antipsychotics | |
Towards defining a rigidity-associated pathogenic pathway in idiopathic parkinsonism | |
Treatment of psychosis in Parkinson's disease | |
Treatment options for rapid-cycling bipolar affective disorder | |
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology | |
A UK consensus on the administration of aripiprazole for the treatment of mania | |
Understanding composition : the expanded guide | |
Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs | |
Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability | |
Use of antacid medication in patients receiving clozapine: a comparison with other second-generation antipsychotics | |
The use of clozapine plasma levels in optimising therapy | |
The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review | |
Valproate as prophylaxis for clozapine-induced seizures: survey of practice | |
Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust | |
Venlafaxine and cardiovascular toxicity | |
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial | |
Volte-faceon venlafaxine – reasons and reflections | |
What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication. | |
Which antidepressant would psychiatrists and nurses from a developing country choose for themselves? | |
Which antipsychotics would mental health professionals take themselves? | |
Which dose of haloperidol? | |
Which first-line antidepressant? | |
Zuclopenthixol acetate (Clopixol Acuphase) for rapid sedation | |
モーズレイ精神科における身体疾患の診療ガイドライン |